Telix gained FDA alignment to advance ProstACT Global Phase 3 into U.S. Part 2 for TLX591-Tx in mCRPC, with safety data from Part 1 deemed sufficient. The trial will combine the therapy with abiraterone, enzalutamide, or docetaxel, pending IND amendment review.
New research and precision radiation techniques aim to minimize debilitating side effects of head and neck cancer treatment, including oral mucositis, while maintaining tumor control and improving patient quality of life.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07802977 |
Intraparenchymal Salivary Gland Corticosteroid Injection to Prevent Radiation-Induced Xerostomia |
COMPLETED | PHASE1 |
